AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19479852
Drug: anti-IFNalpha monoclonal
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: anti-IFNalpha monoclonal antibody (mAb) therapy
Trial: 14656555
Drug: Comorbid PTSD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comorbid PTSD and AD treatment group
Trial: 14656555
Drug: PTSD alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTSD alone treatment group
Trial: 14656555
Drug: AD alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AD alone treatment group
Trial: 29385578
Drug: NRT patches
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NRT patches with prescribed doses of oral NRT
Trial: 15599137
Drug: Bupivacaine (0.5%)
RxNorm normalized name: bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupivacaine (0.5%) + S(+) ketamine (75 mg)
Trial: 15599137
Drug: Bupivacaine (0.5%)
RxNorm normalized name: bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupivacaine (0.5%) + Ketorolac (60 mg)
Trial: 8130055
Drug: Alfentanil 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil 1 mg as a bolus i.v. injection 15 s before propofol
Trial: 31299077
Drug: ELISA threshold
RxNorm normalized name: pseudopterogorgia elisabethae extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ELISA threshold of 51.7 ELISA units/mL
Trial: 28701597
Drug: Milrinone low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Milrinone low-dose infusion at 0.375 μg/kg/min
Trial: 28701597
Drug: Milrinone medium-dose
RxNorm normalized name: Milrinone
DrugBank: Milrinone (DB00235)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Milrinone medium-dose infusion at 0.5 μg/kg/min
Trial: 28701597
Drug: Milrinone high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milrinone high-dose infusion at 0.75 μg/kg/min
Trial: 25307771
Drug: 10% neutral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% neutral buffered formalin solution (NBF)
Trial: 21929764
Drug: Terlipressin (TP)
DrugBank: Terlipressin (DB02638)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terlipressin (TP) 1 μg/kg/hour
Trial: 17068314
Drug: Sertraline (selective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (selective serotonin reuptake inhibitor); specific dosage and duration not mentioned.
Trial: 12640354
Drug: Cefaclor (CEF)
RxNorm normalized name: Cefaclor
DrugBank: Cefaclor (DB00833)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefaclor (CEF) 20 mg/kg/d for 10 days
Trial: 12640354
Drug: Amoxicillin/clavulanate (AMC)
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin/clavulanate (AMC) 25 mg/kg/d for 10 days
Trial: 9344167
Drug: Oral controlled-release
RxNorm normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral controlled-release (CR)
Trial: 9344167
Drug: Transdermal (TDD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal (TDD)
Trial: 9344167
Drug: Oral transmucosal
RxNorm normalized name: Thrive, 2 mg oral transmucosal gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral transmucosal (TMD)
Trial: 8199078
Drug: Continuous oestrogen/progestin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous oestrogen/progestin treatment
Trial: 8199078
Drug: Cyclic sequential
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclic sequential oestrogen/progestin treatment
Trial: 8199078
Drug: Five years
RxNorm normalized name: HISTA-FIVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five years treatment with oestradiol/norethisterone
Trial: 2889258
Drug: Famotidine 5
RxNorm normalized name: Famotidine
DrugBank: Famotidine (DB00927)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Famotidine 5 mg
Trial: 19467049
Drug: Heat treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heat treatment at 440 degrees C for 30 min
Trial: 19467049
Drug: Heat treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heat treatment at 440 degrees C for 10 min
Trial: 19467049
Drug: Heat treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heat treatment at 500 degrees C for 30 min
Trial: 19467049
Drug: Heat treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heat treatment at 500 degrees C for 10 min
Trial: 16461145
Drug: Wheat (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wheat (25 g)
Trial: 16461145
Drug: Provocation dose
RxNorm normalized name: OCTINOXATE 0.072 g in 1 g TOPICAL LIPSTICK [EFFET PARFAIT ROUGE AMPLIFIER AMPLIFYING SPF 15 (ROUGE PROVOCATION) - RED]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Provocation dose
Trial: 11771000
Drug: Histamine phosphate
RxNorm normalized name: Histamine Phosphate
DrugBank: Histamine (DB05381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Histamine phosphate at a concentration of 4 mg/mL
Trial: 7684512
Drug: Calcitriol (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcitriol (0.5 to 1.0 microgram per day orally) plus placebo nasal spray
Trial: 7684512
Drug: Calcium (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium (1000 mg per day orally)
Trial: 2963380
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of carbazochrome sodium sulfonate (AC-17)
Trial: 30511966
Drug: Active low-level
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active low-level laser therapy (Riancorp LTU-904)
Trial: 30511966
Drug: Inactive low-level
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive low-level laser therapy (placebo)
Trial: 24959347
Drug: Steroid-free immunosuppressive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid-free immunosuppressive protocol based on low-dose tacrolimus and mycophenolate mofetil (MMF) with antithymocyte globulin (ATG) induction
Trial: 24959347
Drug: Conventional immunosuppressive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional immunosuppressive protocol based on low-dose tacrolimus, MMF, and steroids with interleukin-2 receptor (IL2-R) induction
Trial: 22430565
Drug: MRI after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MRI after surgical debridement and initiation of antibiotic therapy
Trial: 20593535
Drug: gemcitabine 1000
RxNorm normalized name: gemcitabine 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gemcitabine 1000 mg/m2 on days 1 and 8 plus carboplatin area under the curve 5.5 on day 1 (n = 47)
Trial: 20593535
Drug: gemcitabine 1000
RxNorm normalized name: gemcitabine 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gemcitabine 1000 mg/m2 on days 1 and 8 plus paclitaxel 200 mg/m2 on day 1 (n = 42)
Trial: 20593535
Drug: paclitaxel 225
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: paclitaxel 225 mg/m2 on day 1 plus carboplatin area under the curve 6.0 on day 1 (n = 49)
Trial: 20593535
Drug: Standard chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chemotherapy doublet regimens (overall for white and African American patients)
Trial: 9244228
Drug: Clonidine (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (0.1 mg)
Trial: 3100312
Drug: Etidronate 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etidronate 7.5 mg kg‐1 body weight
Trial: 21160258
Drug: Chemotherapy for
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy for older women with high-risk breast cancer features
Trial: 21160258
Drug: Surgery, endocrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery, endocrine therapy, and radiotherapy
Trial: 19670189
Drug: Tacrolimus therapy
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus therapy
Trial: 15988077
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (diuretics, ACE inhibitors, beta-blockers, digoxin)
Trial: 12717125
Drug: Pancuronium 15
RxNorm normalized name: pancuronium
DrugBank: Pancuronium (DB01337)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pancuronium 15 microg/kg followed by mivacurium 0.1 mg/kg
Trial: 12717125
Drug: Saline followed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline followed by mivacurium 0.13 mg/kg
Trial: 2058827
Drug: Fentanyl group
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl group (n = 10): bolus injections of about 0.2 mg/h fentanyl and 2.5 mg/h midazolam
Trial: 2058827
Drug: Ketamine group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine group (n = 10): infusion of about 50 mg/h ketamine and 2.5 mg/h midazolam
Trial: 6327346
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg terbutaline sulphate orally
Trial: 6327346
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg terbutaline sulphate subcutaneously
Trial: 22577718
Drug: Antithyroid drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithyroid drug and Caltrate D (600 mg/day)
Trial: 22577718
Drug: Antithyroid drug,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithyroid drug, Caltrate D (600 mg/day), and Alendronate (70 mg weekly)
Trial: 10442322
Drug: Ossein-hydroxyapatite compound
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ossein-hydroxyapatite compound (OHC) 3.32 g/d
Trial: 10442322
Drug: Calcium carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium carbonate 2.5 g/d
Trial: 2359576
Drug: Daily home
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily home uterine activity monitoring and perinatal nursing support
Trial: 26346408
Drug: TDM (therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TDM (therapeutic drug monitoring)
Trial: 26346408
Drug: Standard dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dosing (clinician-driven)
Trial: 22974254
Drug: Beraprost sodium
RxNorm normalized name: beraprost sodium
DrugBank: Beraprost (DB05229)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beraprost sodium (BPS) 40 µg, tid for 8 weeks
Trial: 17896582
Drug: Alpha-ketoglutaric acid
RxNorm normalized name: Alpha-ketoglutaric acid
DrugBank: Oxogluric acid (DB08845)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-ketoglutaric acid calcium salt (6 g AKG and 1.68 Ca/day)
Trial: 14719145
Drug: Laxative group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laxative group (lactulose)
Trial: 12439361
Drug: Fenoldopam; specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenoldopam; specific agonism of dopamine‐1 receptors; details on dosage and duration not available
Trial: 9625684
Drug: Enalapril, 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril, 10 mg/d
Trial: 7948230
Drug: Trial solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trial solution (1.36% glucose and 1% peptides, 381 mOsm/kg)
Trial: 7948230
Drug: Control solution
RxNorm normalized name: Nausea Control Solution
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control solution (2.27% glucose, 404 mOsm/kg)
Trial: 28559862
Drug: Experimental treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental treatment (EXP) - Treatment as Usual plus Cognitive Behavioral Therapy for psychosis, Family Intervention for psychosis, and Case Management.
Trial: 28559862
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as Usual (TAU) - Personalized outpatient psychopharmacological treatment and non-specific supportive clinical management.
Trial: 28559862
Drug: Experimental treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental treatment (EXP) - Family Intervention for psychosis.
Trial: 28559862
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as Usual (TAU) - No specific family intervention.
Trial: 25540274
Drug: Tdap-IPV followed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tdap-IPV followed by HepB dose 1 month later (Group 1, n = 145)
Trial: 25540274
Drug: Tdap-IPV and
RxNorm normalized name: acellular pertussis vaccine, inactivated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tdap-IPV and HepB administered simultaneously (Group 2, n = 135)
Trial: 23545612
Drug: Crossover to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crossover to the other drug after initial treatment
Trial: 21762177
Drug: Intravenous alcohol
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous alcohol (targeting 40 mg% in 5 minutes) administered immediately after the Trier Social Stress Test (Alc0, n = 11)
Trial: 21762177
Drug: Intravenous alcohol
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous alcohol (targeting 40 mg% in 5 minutes) administered 30 minutes after the Trier Social Stress Test (Alc30, n = 14)
Trial: 21762177
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered 30 minutes after the Trier Social Stress Test (Alc0 group)
Trial: 21762177
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered immediately after the Trier Social Stress Test (Alc30 group)
Trial: 16601576
Drug: Hydrochlorothiazide (alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (alone or in combination with atenolol)
Trial: 16601576
Drug: Candesartan (alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan (alone or in combination with felodipine)
Trial: 14651725
Drug: KT3‐671 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KT3‐671 40 mg
Trial: 14651725
Drug: KT3‐671 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KT3‐671 80 mg
Trial: 14651725
Drug: KT3‐671 160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KT3‐671 160 mg
Trial: 14651725
Drug: KT3‐671 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KT3‐671 (all doses)
Trial: 8733487
Drug: Tobramycin administered
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tobramycin administered eight hourly aiming for a peak concentration of 10 mg/l and trough below 2 mg/l (Group A)
Trial: 8733487
Drug: Tobramycin administered
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tobramycin administered as two equal 12 hourly doses (Group B)
Trial: 1444287
Drug: Didanosine 375
RxNorm normalized name: DIDANOSINE 375MG/PKG SOLN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Didanosine 375 mg alone
Trial: 1444287
Drug: Didanosine 375
RxNorm normalized name: DIDANOSINE 375MG/PKG SOLN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Didanosine 375 mg with ranitidine 150 mg (ranitidine given 2 h prior)
Trial: 1444287
Drug: Ranitidine 150
RxNorm normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranitidine 150 mg alone
Trial: 1444287
Drug: Ranitidine 150
RxNorm normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranitidine 150 mg with didanosine 375 mg
Trial: 15372199
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin type A (BTX‐A) injection
Trial: 30068305
Drug: Placebo injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injection (saline solution)
Trial: 26840904
Drug: Resistance Training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resistance Training (RT) program, twice per week for 12 weeks
Trial: 22425913
Drug: Carboplatin/gemcitabine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboplatin/gemcitabine with eicosanoid modulators (celecoxib, zileuton, or both)
Trial: 19173165
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (Groups B and C)
Trial: 8989740
Drug: Low-protein diet
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-protein diet (0.58 g/kg per day)
Trial: 7594128
Drug: Very-low-protein diet
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Very-low-protein diet (0.28 g/kg per day) with ketoacid-amino acid supplement (0.28 g/kg per day)
Trial: 7594128
Drug: Usual-protein diet
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual-protein diet (1.30 g/kg per day)
Trial: 7031186
Drug: Epsilon aminocaproic
RxNorm normalized name: Epsilon Aminocaproic Acid
DrugBank: Aminocaproic acid (DB00513)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epsilon aminocaproic acid (EACA), 36 g/day
Trial: 7031186
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (TEA), 6 g/day
Trial: 29152243
Drug: Pomegranate extract
RxNorm normalized name: Pomegranate Extract
DrugBank: Pomegranate (DB14317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pomegranate extract (PE) capsules for 8 weeks
Trial: 25799722
Drug: Prolit super
RxNorm normalized name: Prolia
DrugBank: Denosumab (DB06643)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Prolit super (4 capsules daily for 2 months)
Trial: 19042161
Drug: Galantamine (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galantamine (24 mg/day)
Trial: 12269648
Drug: Budesonide aqueous
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide aqueous nasal spray, 128 microg once daily
Trial: 2653555
Drug: Phenylpropanolamine hydrochloride
RxNorm normalized name: Phenylpropanolamine Hydrochloride
DrugBank: Phenylpropanolamine (DB00397)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenylpropanolamine hydrochloride 50 mg bd (Kontexin)
Trial: 2653555
Drug: Oxybutynin chloride
RxNorm normalized name: Oxybutynin Chloride
DrugBank: Oxybutynin (DB01062)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxybutynin chloride 5 mg tid (Ditropan)
Trial: 2653555
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (Phenylpropanolamine and Oxybutynin)
Trial: 24119227
Drug: Other immunosuppressive
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other immunosuppressive agents
Trial: 21208594
Drug: TEAM intervention
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TEAM intervention (depression care management intervention focusing on optimizing antidepressant therapy through patient education, symptom monitoring, adherence promotion, and side-effect management)
Trial: 9286851
Drug: mibefradil 100
RxNorm normalized name: mibefradil 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mibefradil 100 mg once daily
Trial: 9286851
Drug: diltiazem CD
RxNorm normalized name: Diltiazem Hydrochloride 300 MG Oral Capsule, Extended Release, 24 HR [DILTIAZEM CD]
DrugBank: Diltiazem (DB00343)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: diltiazem CD 360 mg once daily
Trial: 9286851
Drug: nifedipine SR
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: nifedipine SR 40 mg twice daily
Trial: 9286851
Drug: amlodipine 10
RxNorm normalized name: amlodipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: amlodipine 10 mg once daily
Trial: 9286851
Drug: nifedipine GITS
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: nifedipine GITS 60 mg once daily
Trial: 3490807
Drug: Intermittent electrical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent electrical stimulation of the muscles of the legs (external electrodes), performed daily 2 X 30 min during the stimulation period (S)
Trial: 20723593
Drug: Liu wei
RxNorm normalized name: Bai Liu Bark
DrugBank: Salix alba bark (DB14274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liu wei di huang wan (LDW), 12 pills, 0.2 g/pill, twice daily for 14 days
Trial: 8012860
Drug: Nedocromil sodium
RxNorm normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nedocromil sodium (NS) 4 mg
Trial: 31738150
Drug: Intradermal sterile
RxNorm normalized name: Steril-Eyes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal sterile water (0.5 ml)
Trial: 31738150
Drug: Intravenous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous morphine (0.1 mg/kg plus 0.5 ml of intradermal sterile water)
Trial: 27921276
Drug: Selumetinib (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selumetinib (oral MEK inhibitor)
Trial: 26155923
Drug: Inhaled corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroids (Flovent HFA)